Clinical Trial Update: A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in previously untreated metastatic colorectal cancer patients unsuitable for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Capecitabine (Xeloda) (Capecitabine)
• S 95005 (S95005)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16